PubMed Health⌕ Search

PubMed · 6311080

Vitamin D: recent advances.

Abstract

The field of vitamin D metabolism and mechanism of action has continued to be very active. Autoradiography has shown specific nuclear localization of 1,25-(OH)2D3 in target organs prior to initiation of mechanism of action. Specific nuclear localization has also been demonstrated in a variety of other tissues not previously appreciated as targets of vitamin D action, suggesting the possibility that vitamin D carries out subtle functions previously unappreciated. A macromolecule believed to be a receptor that specifically binds 1,35-(OH)2D3 has been found in the cells showing nuclear localization and in a number of tumor and cancer cell lines. Since 1,25-(OH)2D3 has been found to cause differentiation of certain myeloid leukemia cells, a possible relationship between the vitamin D system and cancer has appeared. Substantial evidence exists that 1,25-(OH)2D3 functions in a nuclear-mediated process, although some evidence exists that not all of the actions of 1,25-(OH)2D3 are carried out through such a mechanism. Substantial advances in our understanding of the metabolism of vitamin D have also been made. The presence of significant amounts of 1 alpha-hydroxylase has been located in the placenta in addition to the kidney. Although there have been reports of extrarenal synthesis of 1,25-(OH)2D3, these sites, if they produce 1,25-(OH)2D3, produce it in insufficient amounts for function. The renal 1 alpha-hydroxylase has been solubilized and shown to be a three-component system. The 25-hydroxylase in the liver has also been solubilized and shown to be a two-component mixed-function monooxygenase. New pathways of vitamin D metabolism include a 23-oxidation to form 23,25-(OH)2D3 or a 23-hydroxylated form of 1,25-(OH)2D3. 23,25-(OH)2D3 is further oxidized to produce a 25-(OH)2D3-26,23-lactone. Although these pathways are of significant magnitude, their roles remain unknown since the products have low biological activity. Important analogs of the vitamin D metabolites include 24,24-F2-25-OH-D3 and the 26,26,26,27,27,27-F6-25-OH-D3. These have been used to show that the 24-hydroxylation, the 26-hydroxylation, and the lactone formation do not play a significant role in the function of vitamin D. Their 1-hydroxy analogs have also been prepared and shown to be extremely biologically active, being somewhere around ten times more active than the native 1,25-dihydroxyvitamin D3, illustrating that important analogs of the vitamin D system continue to be discovered.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H F DeLuca, H K Schnoes. 1983. Vitamin D: recent advances.. https://doi.org/10.1146/annurev.bi.52.070183.002211

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients.

1,25(OH)(2)D(3) and 25(OH)D(3) have been associated with type 1 diabetes. Diverse enzymes are involved in the synthesis of these metabolites: the 25-Vitamin-D-hydroxylase (CYP2R1), the 25-hydroxyvitamin-D(3)-1-alpha-hydroxylase (CYP27B1) and the 25(OH)D(3)-24-hydroxylase (CYP24) among others. Serum levels of 25(OH)D(3) and 1,25(OH)(2)D(3) were investigated in type 1 diabetes patients (n=173) and the mRNA expression of the CYP2R1, CYP27B1 and CYP24 genes in type 1 diabetes patients (n=33) and healthy controls (n=23). These parameters were correlated with the -1260 (C/A) polymorphism in the CYP27B1 gene. Lower expression of CYP27B1 mRNA in comparison with healthy controls (1.7165 versus 1.7815, P=0.0268) was found. Additionally, patients carrying the genotype CC possessed a reduced amount of CYP27B1 mRNA compared to healthy controls (1.6855 versus 1.8107, respectively, P=0.0220). The heterozygosity rate of the -1260 C/A polymorphism was more frequent in patients with normal levels of 1,25(OH)(2)D(3) (> or =19.9 pmol/ml) than in whose with a level of less than 19.9 pmol/ml (46.7% versus 22.2%, P=0.0134). No correlation with serum levels of 25(OH)D(3) was found. Thus, CYP27B1 gene could play a functional role in the pathogenesis of type 1 diabetes through modulation of its mRNA expression and influence serum levels of 1,25(OH)(2)D(3) via the -1260 C/A polymorphism.

25-Hydroxyvitamin D3 1-alpha-Hydroxylase↗

Parathyroid hormone stimulation of the renal 25-hydroxyvitamin D-1alpha-hydroxylase--effect of age and free radicals.

The capacity of parathyroid hormone (PTH) to increase serum 1,25(OH)(2)D levels declines with age in both rats and humans. In young rats, PTH stimulates renal 1,25(OH)(2)D production and increases mRNA levels for the terminal mitochondrial P450 of the 1alpha-hydroxylase complex (CYP27B1 or CYP1alpha). However, in older rats PTH increases mRNA levels but not 1,25(OH)(2)D production. This suggests that in old animals there is either decreased CYP1alpha protein levels in response to PTH or that the protein produced lacks functionality. The CYP1alpha protein is located on the inner mitochondrial membrane, the site of increased free radical production with age. To study these possibilities, we examined the effect of PTH and free radicals on CYP1alpha expression in a model system-AOK-B50 renal tubular cells. PTH increased CYP1alpha mRNA and protein in a similar time-dependent manner, suggesting that CYP1alpha protein levels were largely regulated by mRNA levels. The effect of free radicals was determined by preincubation with hydrogen peroxide (H(2)O(2)), a standard model for studying free radical damage. H(2)O(2) inhibited PTH-stimulated CYP1alpha protein levels and 1,25(OH)(2)D production in a dose dependent manner. However, 1,25(OH)(2)D production was more sensitive to H(2)O(2) than was CYP1alpha protein levels. This suggests that the catalytic activity of the CYP1alpha protein may be reduced by free radical damage in these cells. Future studies will focus on detecting oxidative damage in this model system and in vivo.

25-Hydroxyvitamin D3 1-alpha-Hydroxylase↗

Role of oncoprotein growth factor independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): a comparative analysis in human prostate cancer and kidney cells.

1,25-Dihydroxyvitamin D (1,25D) inhibits growth of prostate cancer cells and has been proposed to play a protective role in prostate cancer. However, 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1), the enzyme responsible for the cellular synthesis of 1,25D, is repressed in prostate cancer cells. Recently, we have identified a role for the transcription factor, Growth Factor Independent-1 (GFI1) in the repression of the CYP27B1 gene in human prostate cancer cell lines. GFI1 is known to form a large protein complex with co-repressors that recruit histone deacetylases. We have proposed a model for the molecular repression of CYP27B1 gene expression. The formation of such a repressive complex on the inhibitory domain of the CYP27B1 gene in prostate cancer cells could lead to the silencing of gene expression either by inactivating nearby enhancer or proximal promoter domains and lead to cancer progression by reducing local production of 1,25D. These studies demonstrate that GFI1 may play a significant role in the down regulation of endogenous production of 1,25D in prostate cancer cells and could provide a novel insight to future diagnosis and treatment.

25-Hydroxyvitamin D3 1-alpha-Hydroxylase↗